drugset
drugset / Trial / NCT04064125

Dermal Cumulative Irritant Patch Study

NCT04064125 ↗

Phase 1 Completed 42 enrolled Vyne Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of FMX-101 in Healthy Volunteers Using a Cumulative Irritant Patch Test Design

Timeline

Start
2016-09-01
Primary completion
2016-09-28
Completion
2016-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject FMX-101 Unknown — —

Indications

No indication recorded.